听力与言语-语言病理学

行为科学

医学伦理学

你正在浏览Therapeutic Advances in Musculoskeletal Disease期刊下所有文献
  • A comprehensive review of the treatment and management of Charcot spine.

    abstract::Charcot spine arthropathy (CSA), a result of reduced afferent innervation, is an occurrence of Charcot joint, a progressive, degenerative disorder in vertebral joints, related mostly to spinal cord injury. The repeated microtrauma is a result of a lack of muscle protection and destroys cartilage, ligaments, and disc s...

    journal_title:Therapeutic advances in musculoskeletal disease

    pub_type: 杂志文章,评审

    doi:10.1177/1759720X20979497

    authors: Urits I,Amgalan A,Israel J,Dugay C,Zhao A,Berger AA,Kassem H,Paladini A,Varrassi G,Kaye AD,Miriyala S,Viswanath O

    更新日期:2020-12-17 00:00:00

  • Statins, bone biology and revision arthroplasty: review of clinical and experimental evidence.

    abstract::Osteoarthritis is a painful, disabling condition which is increasing in prevalence as a result of an ageing population. With no recognized disease-limiting therapeutics, arthroplasty of the hip and knee is the most common and effective treatment for lower limb osteoarthritis, however lower limb arthroplasty has a fini...

    journal_title:Therapeutic advances in musculoskeletal disease

    pub_type: 杂志文章,评审

    doi:10.1177/1759720X20966229

    authors: Sorial AK,Anjum SA,Cook MJ,Board TN,O'Neill TW

    更新日期:2020-12-16 00:00:00

  • Management of primary and secondary osteoporosis in children.

    abstract::Osteoporosis in children differs from adults in terms of definition, diagnosis, monitoring and treatment options. Primary osteoporosis comprises primarily of osteogenesis imperfecta (OI), but there are significant other causes of bone fragility in children that require treatment. Secondary osteoporosis can be a result...

    journal_title:Therapeutic advances in musculoskeletal disease

    pub_type: 杂志文章,评审

    doi:10.1177/1759720X20969262

    authors: Sakka SD,Cheung MS

    更新日期:2020-11-02 00:00:00

  • Tuberculosis and targeted synthetic or biologic DMARDs, beyond tumor necrosis factor inhibitors.

    abstract::Patients with autoimmune rheumatic diseases (ARD) have an increased risk for tuberculosis (TB). The use of tumor necrosis factor inhibitors (TNFi) and glucocorticoids in these patients has been associated with an increased prevalence of latent TB reactivation. Over the last few years, several biologic disease-modifyin...

    journal_title:Therapeutic advances in musculoskeletal disease

    pub_type: 杂志文章,评审

    doi:10.1177/1759720X20930116

    authors: Evangelatos G,Koulouri V,Iliopoulos A,Fragoulis GE

    更新日期:2020-06-22 00:00:00

  • Biologic therapy and spinal radiographic progression in patients with axial spondyloarthritis: A structured literature review.

    abstract::We aimed to perform a structured literature review of spinal radiographic progression, as assessed by the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS), in patients with ankylosing spondylitis (AS) or nonradiographic axial spondyloarthritis (nr-axSpA) treated with biologic therapy. Searches were limited t...

    journal_title:Therapeutic advances in musculoskeletal disease

    pub_type: 杂志文章,评审

    doi:10.1177/1759720X20906040

    authors: Baraliakos X,Gensler LS,D'Angelo S,Iannone F,Favalli EG,de Peyrecave N,Auteri SE,Caporali R

    更新日期:2020-03-04 00:00:00

  • The role of microbiome in rheumatoid arthritis treatment.

    abstract::Rheumatoid arthritis (RA) is an autoimmune disorder with multifactorial etiology; both genetic and environmental factors are known to be involved in pathogenesis. Treatment with disease-modifying antirheumatic drugs (DMARDs) plays an essential role in controlling disease progression and symptoms. DMARDs have immunomod...

    journal_title:Therapeutic advances in musculoskeletal disease

    pub_type: 杂志文章,评审

    doi:10.1177/1759720X19844632

    authors: Bodkhe R,Balakrishnan B,Taneja V

    更新日期:2019-07-30 00:00:00

  • Functional risk for fracture by safe functional motion testing: a short version of the safe functional motion test.

    abstract:Background:'Unsafe' movement strategies used to perform everyday activities were quantified using scores for tasks included in the Short Form Safe Functional Motion test series (SSFM). Baseline scores were independently associated with incident fractures after adjusting for factors known to effect fracture risk. The pu...

    journal_title:Therapeutic advances in musculoskeletal disease

    pub_type: 杂志文章

    doi:10.1177/1759720X19856012

    authors: Recknor CP,Van Dussen D,MacIntyre N,Recknor J

    更新日期:2019-06-24 00:00:00

  • Effectiveness of healthcare educational and behavioral interventions to improve gout outcomes: a systematic review and meta-analysis.

    abstract:Background:We aimed to systematically review the effectiveness of healthcare behavioral and education interventions for gout patients on clinical outcomes. Methods:We searched multiple databases to identify trials or observational studies of educational or behavioral interventions in gout. Risk of bias was assessed wi...

    journal_title:Therapeutic advances in musculoskeletal disease

    pub_type: 杂志文章,评审

    doi:10.1177/1759720X18807117

    authors: Ramsubeik K,Ramrattan LA,Kaeley GS,Singh JA

    更新日期:2018-11-19 00:00:00

  • Corrigendum.

    abstract::[This corrects the article DOI: 10.1177/1759720X18776224.]. ...

    journal_title:Therapeutic advances in musculoskeletal disease

    pub_type: 杂志文章,已发布勘误

    doi:10.1177/1759720X18807548

    authors:

    更新日期:2018-10-08 00:00:00

  • Hypophosphatemia in the setting of metabolic bone disease: case reports and diagnostic algorithm.

    abstract::Osteoporosis is the most commonly encountered metabolic bone disease, and metabolic bone-disease clinics have been established to assist in the diagnosis and treatment of uncommon causes of low bone-mineral density. Hypophosphatemia leading to metabolic bone disease may be encountered, and an understanding of phosphat...

    journal_title:Therapeutic advances in musculoskeletal disease

    pub_type:

    doi:10.1177/1759720X18779761

    authors: Day AL,Morgan SL,Saag KG

    更新日期:2018-07-01 00:00:00

  • Anti-interleukin and interleukin therapies for psoriasis: current evidence and clinical usefulness.

    abstract::Anti-interleukin (IL) therapies have emerged as a major treatment for patients with moderate-to-severe psoriasis. This article reviews the up-to-date results of pivotal clinical trials targeting the interleukins used for the treatment of psoriasis, including IL-1, IL-2, IL-6, IL-8, IL-10, IL-12, IL-17, IL-20, IL-22, I...

    journal_title:Therapeutic advances in musculoskeletal disease

    pub_type: 杂志文章,评审

    doi:10.1177/1759720X17735756

    authors: Tsai YC,Tsai TF

    更新日期:2017-11-01 00:00:00

  • Intravenous zoledronate for osteoporosis: less might be more.

    abstract::Annual administration of 5 mg intravenous zoledronate is moderately effective in reducing fracture risk in older adults, decreasing the relative risk of clinical fracture by 33%. However, almost 10 years after its approval for use in clinical practice there remain very substantial uncertainties about the optimal treat...

    journal_title:Therapeutic advances in musculoskeletal disease

    pub_type: 杂志文章,评审

    doi:10.1177/1759720X16650866

    authors: Grey A

    更新日期:2016-08-01 00:00:00

  • Effects of denosumab on bone density, mass and strength in women with postmenopausal osteoporosis.

    abstract::Denosumab is a human monoclonal antibody which specifically blocks receptor activator of nuclear factor κB ligand and is a very potent antiresorptive drug. Its efficacy in reducing the risk of vertebral, hip and nonskeletal fracture has been proven in a large prospective, randomized multicenter study of 7808 postmenop...

    journal_title:Therapeutic advances in musculoskeletal disease

    pub_type: 杂志文章,评审

    doi:10.1177/1759720X15579189

    authors: Törring O

    更新日期:2015-06-01 00:00:00

  • Inflammatory eye reactions with bisphosphonates and other osteoporosis medications: what are the risks?

    abstract::Inflammatory eye reactions (IERs) are rare but have been associated with medications to treat osteoporosis. The aim of this review is to summarize the current literature on the association between IERs and specific medications to treat osteoporosis (bisphosphonates, selective estrogen receptor modulators, strontium, d...

    journal_title:Therapeutic advances in musculoskeletal disease

    pub_type: 杂志文章,评审

    doi:10.1177/1759720X14566424

    authors: Clark EM,Durup D

    更新日期:2015-02-01 00:00:00

  • Biological therapies for spondyloarthritis.

    abstract::Biological therapies and new imaging techniques have changed the therapeutic and diagnostic approach to spondyloarthritis. In patients with axial spondyloarthritis, tumor necrosis factor α (TNFα) inhibitor treatment is currently the only effective therapy in patients for whom conventional therapy with nonsteroidal ant...

    journal_title:Therapeutic advances in musculoskeletal disease

    pub_type: 杂志文章,评审

    doi:10.1177/1759720X14535512

    authors: Bruner V,Atteno M,Spanò A,Scarpa R,Peluso R

    更新日期:2014-06-01 00:00:00

  • Sarcoidois: is it only a mimicker of primary rheumatic disease? A single center experience.

    abstract:BACKGROUND:Sarcoidosis is known as a T helper 1 lymphocyte (Th1-Ly) mediated disease which can imitate or sometimes accompany many primary rheumatic diseases. The purpose of this study is to share the clinical, demographic and laboratory data of patients presenting with rheumatologic manifestations and diagnosed with s...

    journal_title:Therapeutic advances in musculoskeletal disease

    pub_type: 杂志文章

    doi:10.1177/1759720X13511197

    authors: Kobak S,Sever F,Sivrikoz ON,Orman M

    更新日期:2014-02-01 00:00:00

  • Fibrates as therapy for osteoarthritis and rheumatoid arthritis? A systematic review.

    abstract::Fibrates are used as lipid-lowering drugs to prevent cardiovascular pathology. Fibrates are ligands of peroxisome proliferator-activated receptor α (PPARα). Besides altering lipid metabolism, PPARα ligands exert anti-inflammatory effects on various cell types. In this study, we hypothesized that PPARα agonists exert b...

    journal_title:Therapeutic advances in musculoskeletal disease

    pub_type: 杂志文章

    doi:10.1177/1759720X12468659

    authors: van Eekeren IC,Clockaerts S,Bastiaansen-Jenniskens YM,Lubberts E,Verhaar JA,van Osch GJ,Bierma-Zeinstra SM

    更新日期:2013-02-01 00:00:00

  • The kinase inhibitor tofacitinib in patients with rheumatoid arthritis: latest findings and clinical potential.

    abstract::Macrophages, T and B cells, and neutrophils concentrate mainly into the synovial tissue of rheumatoid arthritis (RA) patients and produce several inflammatory mediators including cytokines. More recently, small molecule inhibitors of signalling mediators which have intracellular targets (mainly in T and B cells) such ...

    journal_title:Therapeutic advances in musculoskeletal disease

    pub_type: 杂志文章

    doi:10.1177/1759720X12470753

    authors: Cutolo M

    更新日期:2013-02-01 00:00:00

  • DUEXIS(®) (ibuprofen 800 mg, famotidine 26.6 mg): a new approach to gastroprotection for patients with chronic pain and inflammation who require treatment with a nonsteroidal anti-inflammatory drug.

    abstract::Chronic pain conditions affect at least 116 million US adults and more than one-third of adults worldwide. Nonsteroidal anti-inflammatory drugs (NSAIDs) are used extensively for the treatment of chronic pain due to their efficacy as anti-inflammatory and analgesic agents. Gastrointestinal toxicity is the most well kno...

    journal_title:Therapeutic advances in musculoskeletal disease

    pub_type: 杂志文章

    doi:10.1177/1759720X12444710

    authors: Bello AE

    更新日期:2012-10-01 00:00:00

  • The role of biologic agents in damage progression in rheumatoid arthritis: indirect comparison of data coming from randomized clinical trials.

    abstract:OBJECTIVES:All biologic agents approved for the treatment of rheumatoid arthritis (RA) have been tested versus methotrexate (MTX) for efficacy on damage progression in several randomized clinical trials (RCTs), but direct head-to-head comparisons have never been conducted. The purpose of this investigation is to analys...

    journal_title:Therapeutic advances in musculoskeletal disease

    pub_type: 杂志文章

    doi:10.1177/1759720X12449082

    authors: Favalli EG,Pregnolato F,Biggioggero M,Meroni PL

    更新日期:2012-08-01 00:00:00

  • Treatment and management of pseudogout: insights for the clinician.

    abstract::Pseudogout and the associated calcium pyrophosphate dihydrate (CPPD)- crystal-related arthropathies are common conditions that present particular management problems in clinical practice as they often affect older patients with multiple medical comorbidities. The epidemiology, metabolic and endocrine disease associati...

    journal_title:Therapeutic advances in musculoskeletal disease

    pub_type: 杂志文章

    doi:10.1177/1759720X11432559

    authors: Macmullan P,McCarthy G

    更新日期:2012-04-01 00:00:00

  • Preference, satisfaction and usability of subcutaneously administered methotrexate for rheumatoid arthritis or psoriatic arthritis: results of a postmarketing surveillance study with a high-concentration formulation.

    abstract:BACKGROUND/OBJECTIVES:This postmarketing surveillance study assessed the preference, satisfaction, usability, and tolerability of subcutaneous self-administration of a high-concentration (50 mg/ml) ready-to-use formulation of methotrexate (MTX) in patients with rheumatoid arthritis or psoriatic arthritis. METHODS:The ...

    journal_title:Therapeutic advances in musculoskeletal disease

    pub_type: 杂志文章

    doi:10.1177/1759720X11431004

    authors: Striesow F,Brandt A

    更新日期:2012-02-01 00:00:00

  • Simplifying Fibromyalgia Assessment: The VASFIQ Brief Symptom Scale.

    abstract:OBJECTIVES:We tested the ability of the VASFIQ, a seven-item scale composed of Fibromyalgia Impact Questionnaire (FIQ) visual analog scales (VASs), to quantify fibromyalgia global disease severity and identify fibromyalgia patients with significant symptoms of fatigue, poor sleep, depression or anxiety. METHODS:Spearm...

    journal_title:Therapeutic advances in musculoskeletal disease

    pub_type: 杂志文章

    doi:10.1177/1759720X11416863

    authors: Boomershine CS,Emir B,Wang Y,Zlateva G

    更新日期:2011-10-01 00:00:00

  • Sternocostoclavicular hyperostosis: a review.

    abstract::Sternocostoclavicular hyperostosis (SCCH) is a chronic inflammatory disorder which presents with erythema, swelling, and pain of the sternoclavicular joint. Approximately one half of patients have acne or pustular lesions with the best described association being with palmoplantar pustulosis (PPP). Extrasternal articu...

    journal_title:Therapeutic advances in musculoskeletal disease

    pub_type: 杂志文章

    doi:10.1177/1759720X11398333

    authors: Carroll MB

    更新日期:2011-04-01 00:00:00

  • The role of synovitis in osteoarthritis.

    abstract::Osteoarthritis (OA) is the most common form of arthritis worldwide yet there is still a lack of effective treatments for this condition. Increasingly, attention has turned to the role of the synovium in OA as it is now recognized, in part from the use of modern imaging techniques, that synovitis is both common and ass...

    journal_title:Therapeutic advances in musculoskeletal disease

    pub_type: 杂志文章

    doi:10.1177/1759720X10378373

    authors: Wenham CY,Conaghan PG

    更新日期:2010-12-01 00:00:00

  • Treatment strategies for osteoarthritis patients with pain and hypertension.

    abstract::Out of 100 patients with osteoarthritis (OA), almost 40 have a concomitant diagnosis of hypertension. Nonsteroidal anti-inflammatory drugs (NSAIDs) and cyclooxygenase-2 (COX-2) inhibitors may trigger a rise in blood pressure (BP), which is more marked in patients with established hypertension. NSAIDs and COX-2 inhibit...

    journal_title:Therapeutic advances in musculoskeletal disease

    pub_type: 杂志文章

    doi:10.1177/1759720X10376120

    authors: Verdecchia P,Angeli F,Mazzotta G,Martire P,Garofoli M,Gentile G,Reboldi G

    更新日期:2010-08-01 00:00:00

  • The efficacy and safety of abatacept in rheumatoid arthritis.

    abstract::Despite important progress in the treatment of rheumatoid arthritis in the last decade, even in the era of tumour necrosis factor (TNF) blockade there is a need for additional therapeutic options in many patients. In recent years three therapies with a distinct mode of action became available: rituximab, an anti-B cel...

    journal_title:Therapeutic advances in musculoskeletal disease

    pub_type: 杂志文章

    doi:10.1177/1759720X09360429

    authors: Westhovens R,Verschueren P

    更新日期:2010-04-01 00:00:00

  • Botulinum toxin therapy for osteoarticular pain: an evidence-based review.

    abstract::Botulinum (BoNT) toxin has been used for its muscle-paralyzing action in conditions such as treatment of wrinkles, cervical dystonia and blephrospasm. There is preclinical and emerging clinical evidence of another mechanism of action of BoNT, namely, an antinociceptive action. In this review, we provide an evidence-ba...

    journal_title:Therapeutic advances in musculoskeletal disease

    pub_type: 杂志文章

    doi:10.1177/1759720X09357113

    authors: Singh JA

    更新日期:2010-04-01 00:00:00

  • Advancing our understanding of osteocyte cell biology.

    abstract::Osteocytes were the forgotten bone cell until the bone community could become convinced that these cells do serve an important role in bone function and maintenance. In this review we trace the history of osteocyte characterization and present some of the major observations that are leading to the conclusion that thes...

    journal_title:Therapeutic advances in musculoskeletal disease

    pub_type: 杂志文章

    doi:10.1177/1759720X09341484

    authors: Guo D,Bonewald LF

    更新日期:2009-04-01 00:00:00